Your SlideShare is downloading. ×
  • Like
ReportsnReports - U.S. Hyaluronic Acid Viscosupplementation Physician Survey 2011
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×

Now you can save presentations on your phone or tablet

Available for both IPhone and Android

Text the download link to your phone

Standard text messaging rates apply

ReportsnReports - U.S. Hyaluronic Acid Viscosupplementation Physician Survey 2011

  • 154 views
Published

This survey report compares usage patters and perceptions of orthopedic specialists regarding hyaluronic acid viscosupplement product, including single injection, 3-injection and 5-injection therapy …

This survey report compares usage patters and perceptions of orthopedic specialists regarding hyaluronic acid viscosupplement product, including single injection, 3-injection and 5-injection therapy regimes. Satisfaction with current offerings is examined in detail, along with the market penetration of single injection products.

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
154
On SlideShare
0
From Embeds
0
Number of Embeds
1

Actions

Shares
Downloads
0
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. U.S. Hyaluronic Acid Viscosupplementation Physician Survey 2011Over 100 orthopedic specialists were surveyed regarding their perceptions and usage ofhyaluronic acid viscosupplementation during the 2011 American Academy of OrthopaedicSurgeons (AAOS) conference.Buy Now: U.S. Hyaluronic Acid Viscosupplementation Physician SurveyBrowse All: Latest Market Research ReportsThis survey report compares usage patters and perceptions of orthopedic specialistsregarding hyaluronic acid viscosupplement product, including single injection, 3-injectionand 5-injection therapy regimes. Satisfaction with current offerings is examined in detail,along with the market penetration of single injection products. The data presented describespractice experience, practice volume and the attitudes of the respondents to the product, aswell as how these factors interact. In addition to physician brand preference, this surveyreport describes the proportion of doctors who would be willing to switch to a singleinjection product like Genzyme’s Synvisc-One®. The results of the survey indicated a highdegree of familiarity with the product within the physician community. There is a generaldivide in the U.S. medical community between HA brands that are used for a majority ofprocedures within a practice. The respondents were asked to rate their satisfaction with thevarious injection products. This in term was compared to the probability of switchingbrands, and the possible motivating reasons for doing so.Table of Content:1.1 OVERVIEW 11.2 RESPONDENT PRACTICE LOCATION 21.3 COMPETING BRANDS 31.4 TRANSITION TO TOTAL KNEE ARTHROPLASTY 41.5 TIME TO PAIN RELIEF AFTER LAST HA INJECTION 51.6 PURCHASING DECISIONS. 61.7 INCENTIVES RECEIVED BY BRAND . 71.8 CANADIAN RESPONDENTS 8SURVEY HIGHLIGHTS 92.1 RESPONDENT CHARACTERISTICS . 92.1.1 Doctor Profile . 92.1.2 Purchasing Channels 92.2 RESPONSE SUMMARY . 102.2.1 Attitudes Toward Products . 10
  • 2. 2.2.2 Product Incentives 102.2.3 Patient Profile. 11RESEARCH METHODOLOGY. 123.1 RESEARCH OVERVIEW 123.2 RESEARCH SERVICES 123.3 SURVEY METHODOLOGY 133.3.1 Step 1: Project Initiation & Team Selection 13Table of Contents3.3.2 Step 2: Sample Population Preparation 153.3.3 Step 3: Preparation, Questionnaire Design & Administration 163.3.4 Step 4: Reporting and Analysis 183.3.5 Step 5: Customer Feedback . 18HYALURONIC ACID VISCOSUPPLEMENTATION SURVEY RESULTS. 194.1 QUESTION 1: YEARS OF PRACTICE . 194.2 QUESTION 2: VISCOSUPPLEMENT INJECTIONS ADMINISTERED PER MONTH 214.2.1 HA Patients Treated per Month 214.2.2 Monthly Patient Volume by Year of Practice 234.3 QUESTION 3: HA UTILIZATION BY BRAND. 254.3.1 HA Utilization by Brand . 254.3.2 HA Brand Preference Verses Practice Volume 304.4 QUESTION 4: REASONS FOR CHOOSING HA BRAND. 324.5 QUESTION 5: LIKELIHOOD OF INCREASING SINGLE INJECTION USE 344.5.1 Likelihood of Increased Use . 344.5.2 Correlation of Increased Use with Satisfaction 364.6 QUESTION 6: SATISFACTION WITH SINGLE INJECTION PRODUCTS. 384.7 QUESTION 7: PERCENTAGE OF HA PATIENTS THAT SUBSEQUENTLY UNDERGO TOTALKNEE ARTHROPLASTY (TKA) 404.8 QUESTION 8: TIME TO TKA AFTER HA AND CONSERVATIVE TREATMENTS. 424.8.1 Time to TKA 424.8.2 Time to TKA by Practice Profile. 444.9 QUESTION 9: HA INJECTION TYPES USED BEFORE TKA 474.10 QUESTION 10: PERCEIVED BRAND PURCHASING INCENTIVES . 504.11 QUESTION 11: NATURE OF INCENTIVES RECEIVED 524.11.1 Incentive Factors Received . 524.11.2 Incentive Factors Received by Brand . 544.12 QUESTION 12: REASONS TO SWITCH TO DIFFERENT HA BRAND. 564.12.1 Reasons to Swtich Brands. 564.12.2 Reasons to Switch Brands by Practice Profile 584.13 QUESTION 13: PATIENT GROUPS RECEIVING THE MOST BENEFIT FROM HA. 594.14 QUESTION 14: IMPORTANCE OF PRICING 614.15 QUESTION 15: PURCHASING CHANNELS. 63
  • 3. Table of Contents4.15.1 Percentage of Respondents by Purchasing Channels. 634.15.2 Importance of Pricing by Purchasing Channel 654.16 QUESTION 16: RESPONDENT CLINICAL SETTING 674.17 QUESTIONS 17 TO 19: TIME TO RELIEF. 694.17.1 Overview of Time to Relief 694.17.2 Question 17: Time to Relief After Single Injection Treatment 714.17.3 Question 18: Time to Relief After 3-Injection Treatment 724.17.4 Question 19: Time to Relief After 5-Injection Treatment 73APPENDIX 1: CANADIAN RESPONDENTS, 2011 . 745.1 QUESTION 1: YEARS OF PRACTICE. 745.2 QUESTION 2: HYALURONIC ACID (HA) VISCOSUPPLEMENT INJECTIONSADMINISTERED PER MONTH 745.3 QUESTION 3: HA UTILIZATION BY BRAND 755.4 QUESTION 4:REASONS FOR CHOOSING HA BRAND. 755.5 QUESTION 5: LIKELIHOOD OF INCREASING SINGLE INJECTION USE 755.6 QUESTION 6: SATISFACTION WITH SINGLE INJECTION PRODUCTS 765.7 QUESTION 7: PERCENTAGE OF HA PATIENTS THAT SUBSEQUENTLY GO ON TOTOTAL KNEE ARTHROPLASTY (TKA) 765.8 QUESTION 8: TIME TO TKA AFTER HA AND CONSERVATIVE TREATMENTS 765.9 QUESTION 9: HA INJECTION TYPES USED BEFORE TKA . 775.10 QUESTION 10: PERCEIVED BRAND PURCHASING INCENTIVES . 775.11 QUESTION 11: NATURE OF INCENTIVES RECEIVED 775.12 QUESTION 12: REASONS TO SWITCH TO DIFFERENT HA BRAND 785.13 QUESTION 13: PATIENT GROUPS RECEIVING THE MOST BENEFIT FROM HA 785.14 QUESTION 14: IMPORTANCE OF PRICING . 785.15 QUESTION 15: PURCHASING CHANNELS. 795.16 QUESTION 16: RESPONDENT CLINICAL SETTING 795.17 QUESTION 17: TIME TO RELIEF AFTER INJECTION. 79APPENDIX 2: SURVEY QUESTIONS. 80List of FiguresLIST OF FIGURESEXECUTIVE SUMMARY. 1SURVEY HIGHLIGHTS . 9RESEARCH METHODOLOGY. 12HYALURONIC ACID VISCOSUPPLEMENTATION SURVEY RESULTS . 19Figure 4-1: Years of Practice, U.S., 2011 . 19Figure 4-2: HA Patients Treated per Month, U.S., 2011 21Figure 4-3: Monthly Patient Volume by Year of Practice, U.S., 2011 . 23Figure 4-4: HA Brand Frequency of Use, Weighted Average, U.S., 2011 25
  • 4. Figure 4-5: HA Brand Frequency of Use by Response Distribution, U.S., 2011. 26Figure 4-6: Practice Profile, Synvisc-One® Majority Use, U.S., 2011 30Figure 4-7: Practice Profile, Three and Five Cycle Majority Use, U.S., 2011 30Figure 4-8: Reasons for Choosing a HA Brand, U.S., 2011 . 32Figure 4-9: Likelihood of Switching to Single Injection, U.S., 2011 . 34Figure 4-10: Satisfaction and Likelihood of Switching to Single Injection for CurrentUsers of Synvisc-One®, U.S., 2011 36Figure 4-11: Average Single Injection Satisfaction Verses Likelihood of IncreasingUsage, U.S., 2011 . 36Figure 4-12: Satisfaction wit Single Injection Products, All Respondents, U.S., 2011 . 38Figure 4-13: Percentage of HA Patients that Subsequently Go on to Total KneeArthroplasty (TKA) , U.S., 2011 . 40Figure 4-14: Time to TKA After HA and Conservative Treatments, Months, U.S.,2011 . 42Figure 4-15: Time to TKA in Months by Practice Profile, Weeks to TKA perPercentage of Patients that Require Surgery, U.S., 2011 44Figure 4-16: HA Injection Types Used before TKA, Weighted Average, U.S., 2011 47Figure 4-17: HA Injection Types Used before TKA by Response Distribution, U.S.,2011 . 48List of FiguresFigure 4-18: Perceived Brand Purchasing Incentives, U.S., 2011 50Figure 4-19: Nature of Incentives Received, U.S., 2011 . 52Figure 4-20: Incentive Factors Received by Brand, U.S., 2011 . 54Figure 4-21: Reasons to Switch to Different HA Brand, U.S., 2011 56Figure 4-22: Percent of Patients Who Undergo TKA for Respondents Choosing BetterClinical Efficacy as a Reason to Switch Brands, U.S., 2011 . 58Figure 4-23: Percent of Patients Who Undergo TKA for Respondents Not ChoosingBetter Clinical Efficacy as a Reason to Switch Brands, U.S., 2011 . 58Figure 4-24: Patient Groups Receiving the Most Benefit from HA 59Figure 4-25: Importance of Pricing, U.S., 2011 61Figure 4-26: Purchasing Channels, U.S., 2011 63Figure 4-27: Importance of Pricing by Purchasing Channel, U.S., 2011 65Figure 4-28: Respondent Clinical Setting, U.S., 2011. 67Figure 4-29: Time to Relief Treatment by Injection Cycle, Weeks, U.S., 2011 69Figure 4-30: Time to Relief After Single Injection Treatment, Weeks, U.S., 2011. 71Figure 4-31: Time to Relief After 3-Injection Treatment, Weeks, U.S., 2011 72Figure 4-32: Time to Relief After 5-Injection Treatment, U.S., 2011 73APPENDIX 1: CANADIAN RESPONDENTS, 2011 74APPENDIX 2: SURVEY QUESTIONS 80
  • 5. List of ChartsLIST OF CHART SEXECUTIVE SUMMARY. 1Chart 1-1: Hyaluronic Acid Usage Among Survey Respondents, U.S., 2011 . 1Chart 1-2: Respondent Location by State, U.S., 2011 . 2Chart 1-3: Percentage of Usage, Selected Brands, U.S., 2011 . 3Chart 1-4: Time from HA Treatment to TKA in Weeks, 2011 . 4Chart 1-5: Time to Relief After Last Injection in Weeks, All Types of HA Injections,U.S., 2011 5Chart 1-6: Reasons for Choosing a HA Brand, U.S., U.S., 2011 6Chart 1-7: Incentives Received by Brand, U.S., 2011 . 7Chart 1-8: Brand Preference, Canadian Respondents, U.S., 2011 8SURVEY HIGHLIGHTS . 9RESEARCH METHODOLOGY. 12HYALURONIC ACID VISCOSUPPLEMENTATION SURVEY RESULTS . 19Chart 4-1: Years of Practice, U.S., 2011 20Chart 4-2: HA Patients per Month, U.S., 2011 22Chart 4-3: Monthly Patient Volume per Year of Practice, U.S., 2011 24Chart 4-4: HA Brand Frequency of Use, Weighted Average, U.S., 2011 . 27Chart 4-5: HA Brand Frequency of Use by Response Distribution, U.S., 2011(Part 1 of 2) 28Chart 4-6: HA Brand Frequency of Use by Response Distribution, U.S., 2011(Part 2 of 2) 29Chart 4-7: Monthly Patients Seen per Month by HA Preference, U.S., 2011 31Chart 4-8: Reasons for Choosing a HA Brand 33Chart 4-9: Likelihood of Switching to Single Injection, U.S., 2011. 35Chart 4-10: Satisfaction and Likelihood of Switching to Single Injection, U.S., 2011 . 37Chart 4-11: Satisfaction wit Single Injection Products 39List of ChartsChart 4-12: Percentage of HA Patients that Subsequently Go on to Total KneeArthroplasty (TKA) , U.S., 2011 . 41Chart 4-13: Time to TKA After HA and Conservative Treatments, U.S., 2011 43Chart 4-14: Time to TKA in Months by Practice Profile, U.S., 2011 . 45Chart 4-15: Time to TKA in Months by Practice Profile, Weeks to TKA perPercentage of Patients that Require Surgery, Response Distribution, U.S., 2011 . 46Chart 4-16: HA Injection Types Used before TKA, Weighted Average, U.S., 2011 . 49Chart 4-17: Perceived Brand Purchasing Incentives 51Chart 4-18: Nature of Incentives Received, U.S., 2011 . 53Chart 4-19: Incentive Factors Received by Brand, U.S., 2011 . 55Chart 4-20: Reasons to Switch to Different HA Brand 57Chart 4-21: Patient Groups Receiving the Most Benefit from HA . 60Chart 4-22: Importance of Pricing, U.S., 2011 . 62
  • 6. Chart 4-23: Purchasing Channels, U.S., 2011 . 64Chart 4-24: Importance of Pricing by Purchasing Channel, U.S., 2011 66Chart 4-25: Respondent Clinical Setting, U.S., 2011 68Chart 4-26: Time to Relief by Treatment Cycle, Weeks, U.S., 2011 70APPENDIX 1: CANADIAN RESPONDENTS, 2011 74APPENDIX 2: SURVEY QUESTIONS 80Related Reports: Asia Pacific Markets for Orthopedic Biomaterials 2011 – Bone Grafting and Hyaluronic Acid Viscosupplementation International Hyaluronic Acid Viscosupplementation Physician Survey 2011 Kidney and Renal Diseases Therapeutics Market to 2017 – Strong Pipeline and Unmet Need Due to Poor Safety Profiles to Create Opportunities for Growth Emerging Market for Clinical Trials in Russia – Curbs on New Drug Approval Timelines and Registration Fees Encourage the Emergence of a Major Global Player Emerging Market for Clinical Trials in Argentina – Major Cost Advantages over the US in Conducting Clinical Trials Will Encourage Drug DevelopmentAbout UsReportsnReports is an online library of over 75,000 market research reports and in-depthmarket research studies & analysis of over 5000 micro markets. We provide 24/7 online andoffline support to our customers. Get in touch with us for your needs of market researchreports.Follow us on: Twitter: http://twitter.com/marketsreports Facebook:http://www.facebook.com/pages/ReportsnReports/191441427571689 Blog : http://www.reportsnreportsblog.com/Contact:Mr.Priyank7557 Rambler road,Suite727,Dallas,TX75231Tel: +1-888-989-8004E-mail: sales@reportsnreports.comWebsite: http://www.reportsnreports.com